{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:23:33Z","timestamp":1771979013777,"version":"3.50.1"},"reference-count":23,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ersjournals.com"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2023,5,25]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:p>Deaths from tuberculosis (TB) reached over 1.6 million in 2021 with 10.6 million people becoming ill. Multidrug-resistant TB, defined as the<jats:italic>Mycobacterium tuberculosis<\/jats:italic>organism having resistance to at least isoniazid and rifampicin, represented 3.9% of new TB cases and 18% of previously treated cases. While new drug regimens continue to be developed and introduced to improve treatment of drug-resistant forms of TB, diagnostic capability to identify drug resistance lags woefully behind. While significant mortality benefits exist for these newer drug regimens, implementing them without proper drug resistance diagnostic capacity could lead to development of more drug resistances and exhaust these new therapeutic tools. Moving forward, the roll-out of new TB drugs and regimens must be paired with implementation of diagnostics to ensure judicious use of resources and the best chance for improving TB worldwide.<\/jats:p>","DOI":"10.1183\/20734735.0084-2023","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T10:30:14Z","timestamp":1689071414000},"page":"230084","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Rolling out new anti-tuberculosis drugs without diagnostic capacity"],"prefix":"10.1183","volume":"19","author":[{"given":"Tara","family":"Ness","sequence":"first","affiliation":[]},{"given":"Le Hong","family":"Van","sequence":"additional","affiliation":[]},{"given":"Ilze","family":"Petermane","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-3099","authenticated-orcid":false,"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[]},{"given":"Dick","family":"Menzies","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6415-1535","authenticated-orcid":false,"given":"Daniela Maria","family":"Cirillo","sequence":"additional","affiliation":[]}],"member":"81","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"2024101704081612000_19.2.230084.1","unstructured":"World Health Organization . Global tuberculosis report 2021. Date last updated: 14 October 2021. www.who.int\/publications\/i\/item\/9789240037021"},{"key":"2024101704081612000_19.2.230084.2","unstructured":"World Health Organization . WHO announces updated definitions of extensively drug-resistant tuberculosis. Date last updated: 27 January 2021. www.who.int\/news\/item\/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis"},{"key":"2024101704081612000_19.2.230084.3","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Date last updated: 21 September 2022. www.who.int\/publications\/i\/item\/9789240046764"},{"key":"2024101704081612000_19.2.230084.4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","article-title":"Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis \u2013 United States, 2022","volume":"71","author":"Carr","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024101704081612000_19.2.230084.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119430"},{"key":"2024101704081612000_19.2.230084.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117166"},{"key":"2024101704081612000_19.2.230084.7","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis. Module 4: treatment: drug-resistant tuberculosis treatment. Date last updated: 15 June 2020. www.who.int\/publications\/i\/item\/9789240007048"},{"key":"2024101704081612000_19.2.230084.8","doi-asserted-by":"crossref","first-page":"100278","DOI":"10.1016\/j.jctube.2021.100278","article-title":"Gaps related to screening and diagnosis of tuberculosis in care cascade in selected health facilities in East Africa countries: a retrospective study","volume":"25","author":"Mnyambwa","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2024101704081612000_19.2.230084.9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024101704081612000_19.2.230084.10","first-page":"CD013359","article-title":"Xpert MTB\/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children","volume":"9","author":"Kay","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101704081612000_19.2.230084.11","first-page":"CD009593","article-title":"Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis","volume":"2","author":"Zifodya","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101704081612000_19.2.230084.12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014841.pub2"},{"key":"2024101704081612000_19.2.230084.13","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3390\/pathogens11111343","article-title":"High throughput sequencing for clinical tuberculosis: an overview","volume":"11","author":"Ness","year":"2022","journal-title":"Pathogens"},{"key":"2024101704081612000_19.2.230084.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00915-19"},{"key":"2024101704081612000_19.2.230084.15","doi-asserted-by":"crossref","first-page":"754249","DOI":"10.3389\/fmicb.2021.754249","article-title":"Primary bedaquiline resistance among cases of drug-resistant tuberculosis in Taiwan","volume":"12","author":"Wu","year":"2021","journal-title":"Front Microbiol"},{"key":"2024101704081612000_19.2.230084.16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00621-2021"},{"key":"2024101704081612000_19.2.230084.17","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00037-14"},{"key":"2024101704081612000_19.2.230084.18","doi-asserted-by":"crossref","first-page":"dlac029","DOI":"10.1093\/jacamr\/dlac029","article-title":"Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review","volume":"4","author":"Mallick","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2024101704081612000_19.2.230084.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00470-9"},{"key":"2024101704081612000_19.2.230084.20","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1473-3099(22)00543-6","article-title":"Balancing access to BPaLM regimens and risk of resistance","volume":"22","author":"Van Rie","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024101704081612000_19.2.230084.21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jinf.2023.01.039","article-title":"Pretomanid-resistant tuberculosis","volume":"86","author":"Koehler","year":"2023","journal-title":"J Infect"},{"key":"2024101704081612000_19.2.230084.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat9689"},{"key":"2024101704081612000_19.2.230084.23","first-page":"190","article-title":"Regimens for drug-resistant tuberculosis","volume":"388","author":"Lange","year":"2023","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1183\/20734735.5084-2023","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000}}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0084-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:58:18Z","timestamp":1729166298000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0084-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,7,11]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1183\/20734735.0084-2023"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0084-2023","relation":{"correction":[{"id-type":"doi","id":"10.1183\/20734735.5084-2023","asserted-by":"object"}]},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}